Skip to Content

Evotaz Approval History

FDA Approved: Yes (First approved January 29, 2015)
Brand name: Evotaz
Generic name: atazanavir and cobicistat
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: HIV Infection

Evotaz (atazanavir and cobicistat) is a once-daily fixed-dose combination of a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Evotaz

Jan 29, 2015Approval FDA Approves Evotaz (atazanavir and cobicistat) for HIV-1 Infection in Adults
Apr 14, 2014Bristol-Myers Squibb Submits NDA to FDA for Fixed-Dose Combination of Atazanavir Sulfate with Cobicistat

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.